COVID-19 mRNA-vaccination and all-cause mortality in the adult population in Norway during 2021-2023: a population-based cohort study

Jesper Dahl¹, German Tapia², Håkon Bøås¹, Inger Johanne Landsjøåsen Bakken³, Hanne Løvdal Gulseth²

- Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway
- 2. Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
- 3. Division of Health Data and Digitalisation, Norwegian Institute of Public Health, Trondheim, Norway

Corresponding author:

Jesper Dahl

Norwegian Institute of Public Health,

P.O. Box 222

0213 Oslo

Norway

E-mail: jesper.dahl@fhi.no

Phone: +47 21 07 70 00

Word count: 2738

References: 21

Abstract

Introduction:

Most countries worldwide have experienced excess mortality that coincides temporally with the COVID-19 mass vaccination campaigns. This has led to speculation on the potential long-term effects of the vaccines on mortality risk.

Methods:

The study was designed as a retrospective cohort study, and included all individuals aged ≥18 years living in Norway during January 1, 2021, through December 31, 2023. Individuals were categorized as either unvaccinated (received no doses), partially vaccinated (received one or two doses) or fully vaccinated (received three or more doses) from the date of vaccination and onwards. Age-stratified Poisson models were used to estimate incidence rate ratios of death (all causes) between vaccination groups, adjusting for sex, calendar time, county of residence and risk group status (nursing home resident or preexisting condition with increased risk of severe COVID-19).

Results:

The study included 4 645 910 individuals (49.8% women) with 132 963 deaths during follow-up. There was a higher proportion of individuals that were part of a risk group among fully vaccinated individuals compared to unvaccinated individuals in all age groups, and a lower unadjusted rate of death: 51.5 vs 73.6 per 100 000 person years (py) among individuals aged 18-44 years, 295.1 vs 405.3 per 100 000 py among 45-64 years, and 3620.2 vs 4783.8 per 100 000 py among 65 years or older. The adjusted IRR of death for the same age groups were 0.42 (95% CI 0.38-0.47), 0.39 (95% CI 0.37-0.41) and 0.42 (95% CI 0.41-0.43), respectively. The differences in rate of death between vaccination groups were larger among men and peaked during 2022.

Conclusion:

Vaccinated individuals had a lower rate of all-cause death during 2021-2023 in Norway.

Key messages

In Norway, as in many Western countries, there has been an excess mortality during 2021-2023, surpassing the numerical count of COVID-19-associated deaths. The excess mortality coincides temporally with the COVID-19 mass vaccination campaigns, but longitudinal data regarding mortality post-vaccination remain sparse. Using real-time national health registry data, we estimate the risk of all-cause mortality by vaccination status in the total adult population in Norway during 2021-2023 and demonstrate a lower rate of all-cause death among vaccinated individuals.

Introduction

Most countries worldwide have experienced increased all-cause mortality during the covid-19 pandemic. This excess mortality has generally been attributed to surges in covid-19 cases(1), but there are still lingering questions as to the indirect effects of the pandemic, such as disruption of health services, on the observed mortality rates(2). Due to the proximity of the widespread implementation of covid-19 vaccination programmes to the observed excess mortality, there has also been speculation as to whether vaccinations can have contributed to the increased mortality risk(3). This has generally been refuted by studies on vaccination effect, which have shown reduced mortality rates among vaccinated individuals (4), and studies presenting no increased mortality in vaccinated individuals(5-9). We have earlier investigated short-term vaccination in the elderly(10). However, follow-up time in these studies is generally limited to <1 year, which has left room for speculations of a potential long-term effect of vaccination on mortality risk. To address these concerns, we aimed to present all-cause mortality rates by vaccination status throughout all periods with observed excess mortality in Norway during the covid-19 pandemic, while accounting for existing medical conditions with increased risk of severe COVID-19.

Methods

Study design

The study was designed as a retrospective cohort study and included all individuals with a national identity number (all permanent residents) aged 18 year or older living in Norway during January 1, 2021, through December 31, 2023. Date of birth, immigration, emigration and death was retrieved from the National Population Register. Each individual could enter follow-up at any point of the study period upon attaining 18 years of age and/or immigrating, and was censored at emigration, death or end of follow-up (December 31, 2023).

Data Source

The Emergency preparedness register for COVID-19 (Beredt C19) was established according to the Health Preparedness Act §2-4 to assess risk and implement measures during the COVID-19 pandemic(11). Beredt C19 receives registry data from mandatory Norwegian health registries and other relevant data sources at varying time intervals, commonly on a weekly basis.

For the current study, we used data originating from the Norwegian Immunisation Registry (SYSVAK), the National Population Register, the Norwegian Patient Registry (NPR) and the Norwegian Registry for Primary Health Care (NRPC), as described in detail below.

All data linkage and analyses were conducted within Beredt C19. Individual-level registry information was linked using the unique personal identification number (pseudonymized) given to every resident at birth or immigration.

Exposure - Vaccination

All covid-19 vaccinations in Norway are mandatorily reported to SYSVAK. Using the type of vaccine and date of vaccination we categorized all person time into "received no doses"

(from here on referred to as "unvaccinated"), "received one or two doses of covid-19 vaccination" (from here on referred to as "partially vaccinated") or "received 3 or more doses of covid-19 vaccination" (from here on referred to as "fully vaccinated"). Each individual was counted as vaccinated from the date of vaccination and onwards, and only changed groups upon receiving a new relevant dose. Only doses with mRNA vaccines were included in the current study: BNT03/Comirnaty, CBA01/Omicron BA.1, CBA45/Comirnaty Omicron BA.4-5, CBB15/Comirnaty Omicron XBB.1.5, MOD03/ Spikevax, SBA01/ Spikevax Omicron BA.1, SBA45/Spikevax Omicron BA.4-5(12). These vaccine types accounted for 98.7% of all covid-19 vaccine doses registered in SYSVAK up until December 31, 2023. If an individual received a dose with another type of covid-19 vaccination, they were censored from the analysis on the day prior to this vaccination.

Outcome - All-cause death

Death from any cause was considered the main outcome in each analysis. Date of death was retrieved from the National Population Register.

Covariates

Each analysis was stratified by age group (18-44 years, 45-64 years and 65 years or older) and included the following covariates: Sex, county of residence, calendar time (quarter and year) and medical risk group at baseline. Each analysis is also presented sex-stratified, with sex being removed as a covariate from the models in question.

Vaccine recommendations in Norway during the study period were in large part based on age, and the given age groups were chosen to reflect these differing recommendations.

Information on sex and county of residence was retrieved from the National Population Register and included as categorical variables.

Information on age was also retrieved from the National Population Register and was handled as a time-varying categorical variable ("18-44 years", "45-64 years" and "65 years or older"), meaning that each individual could change age-groups during follow-up.

Calendar time (quarter and year) was included as a time-varying covariate. Q1 was defined as January 1 through March 31, Q2 as April 1 through June 30, Q3 as July 1 through September 30, and Q4 as October 1 through December 31.

Medical risk group was included as a dichotomous covariate (yes/no). It was defined using the NPR and the NRPHC(13). Any individual on short- or long-term nursing home stay or with a preexisting, predefined risk condition at start of follow-up was considered as being in the risk group. The definition of risk conditions is detailed in Supplemental table 3.

Statistics

Incidence rate ratios (IRR) of all cause death were estimated using age-group stratified Poisson regression models. Estimates were adjusted for the following covariates: Sex (men/women), county of residence (categorical), calendar time (quarter and year, time varying) and medical risk group at baseline (yes/no). Each model was also stratified by sex (women/men) and calendar year (2021-2023). A separate sensitivity analysis was adjusted

for age in 10-year age groups (18-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80-89, ≥90) along with all other described covariates.

COVID-19 vaccination status ("unvaccinated", "partially vaccinated" or "fully vaccinated") was considered the exposure in all models and was handled as a time varying covariate, with each individual changing groups at the vaccination date in question.

IRRs are reported with 95% CIs, with unvaccinated person time as reference. When reporting descriptive data for time varying covariates (age group, vaccination status and calendar time) we report data from the last available point of follow-up for each individual in the given time period. Person time is reported as per 100 000 person years (py).

All analyses were conducted using Stata SE version 18.0 for Windows (StataCorp LLC, College Station, TX).

Ethics

Beredt C19 was established under the Act on Health and Social Preparedness §2-4 to assist national and international authorities in assessing risk and implementing measures during the COVID-19 pandemic, using registry data without informed consent or need for ethical approval. National IDs were pseudonymized with an algorithm recommended by the National Security Authority, and all analyses were in compliance with the data protection impact assessment (DPIA) of Beredt C19. Only anonymous aggregated results were exported from Beredt C19. The study was approved by the Regional Committee for Medical and Health Research Ethics South-East Norway (REK South East A, ref 122745).

Public Involvement

The study addresses a specifically stated public concern using data that was made available during the COVID-19 pandemic to evaluate such questions. However, the public at large was not directly involved in any part of the study design or conduct.

Results

A total of 4 645 910 individuals aged ≥18 years were included during follow-up, with a mean follow-up time of 2.72 years. 3 964 864 individuals (85%) received one or more doses of COVID-19 mRNA vaccines, with 2 898 837 individuals (62%) receiving three or more doses. Vaccinated individuals were on average older than unvaccinated individuals. While 88% of individuals aged 65 years or older received three or more doses during follow-up, this was the case for only 42% among those aged 18-44 years. 20% of those aged 18-44 years did not receive any dose during follow-up, compared to only 5% among those aged 65 years or older. There was also a higher proportion of individuals with a risk condition among those vaccinated compared to those left unvaccinated through the study period (Table 1). These differences in proportion of older individuals and individuals with a risk condition between the different vaccination groups were particularly pronounced during 2021, when individuals at risk were still being prioritized for vaccination ahead of others in Norway (Supplemental table 1).

There was a total of 132 963 deaths during follow-up, with 116 589 (88%) occurring among those 65 years or older. In all age groups, the rate of death was lowest among those that

were fully vaccinated and highest among those that were unvaccinated. The rate of death for those that were fully vaccinated compared to those that were unvaccinated was 30% lower, 27% lower and 24% lower in the age-groups 18-44 years, 45-64 years and 65 years or older (51.5 vs 73.6 per 100 000 py, 295.1 vs 405.3 per 100 000 py and 3620.2 vs 4783.8 per 100 000 py, respectively). This difference in rate of death was higher among men compared to women, particularly in the youngest age group where the difference between men and women was 19%, compared to 8% and 5% in age groups 45-64 years and 65 years or older, respectively (Table 2).

Due to the higher proportion of individuals with a risk condition among those that received a vaccination compared to those that were unvaccinated, these differences in rates of death became more pronounced in the adjusted models. After adjusting for sex, risk condition, county of residence and calendar time the IRR of death among those that were fully vaccinated compared to those that were unvaccinated was 0.42 (95% CI 0.38-0.47) among individuals aged 18-44 years, 0.39 (95% CI 0.37-0.41) among individuals aged 45-64 years, and 0.42 (95% CI 0.41-0.43) among individuals aged 65 years or older (Figure 1). Again, this difference in rate of death between those that were fully vaccinated compared to those that were unvaccinated was higher among men than women, with a 20% lower IRR among men than women among those aged 18-44 years, compared to 8% and 27% among those aged 45-64 years and 65 years or older, respectively (Table 2).

The lowest IRR of death among those that were fully vaccinated compared to those that were unvaccinated occurred during 2022 for all age groups. The only subgroup of our study population that did not have a reduced risk of death among fully vaccinated compared to unvaccinated was individuals aged 18-44 years during 2021 (IRR 0.84, 95% CI 0.47-1.49). However, this estimate was based on a low number of deaths.

As a sensitivity analysis, we included the whole study population (everyone aged ≥18 years) in a separate model where we adjusted for age (categorical 10-year groups) in addition to sex, risk condition, county of residence and calendar time. In this model the fully vaccinated group had an IRR of death of 0.39 (95% CI 0.38-0.40) compared to the unvaccinated group, while those that were partially vaccinated (1-2 doses) had an IRR of 0.64 (95% CI 0.63-0.65) compared to the unvaccinated group (data not shown).

Discussion

Our data show reduced all-cause mortality among vaccinated individuals compared to unvaccinated individuals during 2021-2023 in Norway. This difference in mortality was largest during 2022, after COVID-19 control measures were removed, and higher among men.

These results are generally in accordance with previously published data on vaccine effectiveness and safety(14). There are, however, few studies that have evaluated long-term all-cause mortality by vaccination groups on a general population level, and there have been lingering questions as to the potential impact of vaccines on the increased mortality seen during the COVID-19 pandemic(3). There will always be residual confounding in observational studies that makes it impossible to argue that the vaccine itself is the sole reason for any observed beneficial or detrimental effect, but it nonetheless seems incontrovertible that vaccinated individuals have fared better with regards to mortality risk during the covid-19 pandemic than those that remained unvaccinated.

The main strength of the current study is access to individual-level data from nationwide, high quality, mandatory health registers. Our study population comprises the whole

population of Norway aged 18 years or more during the study period and includes information on covid-19 vaccinations from the mandatory national registry SYSVAK. Apart from those subject to erroneous reporting, the only vaccines not captured are vaccines received abroad and not reported to Norwegian health care personnel.

There will always be a healthy vaccinee bias present in observational studies of vaccination outcomes. We tried to address this by including information on preexisting medical conditions as well as nursing home residency to describe individuals at risk of severe outcomes. As risk group were defined at baseline, we might underestimate the total number of individuals with a risk condition. We do not expect this to have caused an overestimation of the difference in mortality rate between the vaccination groups, since we observed a higher proportion of individuals with risk conditions in the vaccinated groups. It is probably more likely that some people in the unvaccinated group are misclassified as not belonging to a risk group, due to causes for low healthcare seeking behavior such as a refugee background or low socioeconomic status(15, 16). Individuals at end-of-life receiving palliative care would also likely not receive any vaccination. However, this would mainly influence our results during the initial parts of the vaccination programme in 2021.

Vaccine effectiveness studies estimate that the protective effect of mRNA covid-19 vaccines against severe outcomes is significantly reduced six months after administration(17). In the current study we did not impose any time restriction on vaccination status, meaning that an individual remained in their designated vaccination group either until they received a vaccination that changed this, or they were censored from follow-up. This approach was chosen to address the potential existence of detrimental long-term effects of vaccination on mortality risk.

Any potential protective effect of covid-19 vaccination on all-cause mortality is likely predicated on its prevention of serious outcomes following infection. We therefore do not expect a protective effect to be present outside of time periods where there is an ongoing spread of covid-19. The number of COVID-19 cases in Norway remained low during most of 2021 until the removal of most infection control measures during the autumn, with a subsequent peak during the winter of 2021/2022 and multiple waves during 2022, which also coincided with the largest single-year drop in life expectancy in Norway since the Second World War(18, 19). There were 3 505 covid-19 associated deaths reported in Norway during 2022, compared to 965 and 1 546 in 2021 and 2023, respectively(19), and in line with this 2022 is also the part of our study period where the difference in mortality between the fully vaccinated group and the unvaccinated group is the largest. This difference in mortality risk between the vaccination groups was more pronounced among men than women, which is likely related to the increased frequency of severe outcomes following COVID-19 among men(20, 21).

We expect the differences in mortality between the vaccination groups to wane over time, as the protective effect of the vaccine itself is reduced alongside the establishment of natural immunity in the general population. The chosen study period includes the time with the highest mortality during the covid-19 pandemic in Norway but does not include a calendar year with mortality rates closer to pre-pandemic levels and an absence of widespread covid-19. This would have been interesting as a negative control with regards to differences between vaccination groups. As the population gets more booster doses, future work could also compare individuals that only received three doses to those that have regularly received additional boosters.

In conclusion, there was a reduced rate of death among individuals vaccinated with mRNA vaccines during 2021-2023 in Norway.

Acknowledgements

The authors would like to thank Jon Michael Gran for his input regarding study design.

Author Contributions:

Dahl and Tapia had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Gulseth, Dahl, Tapia.

Interpretation of data: All authors.

Drafting of the manuscript: Gulseth, Dahl, Tapia.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Tapia, Dahl.

Administrative, technical, or material support: Gulseth

Conflict of Interest:

The authors report no conflict of interest.

Funding Statement:

No external funding was obtained for this study.

Data sharing:

Owing to data privacy regulations in Norway, the raw data cannot be shared. However, the data are available for research upon reasonable request to The Norwegian Institute of Public Health after approval from the Norwegian Committee for Medical and Health Research Ethics and within the framework of the Norwegian data protection legislation and any required permission from Authorities.

References

- 1. Lewnard JA, B CM, Kang G, Laxminarayan R. Attributed causes of excess mortality during the COVID-19 pandemic in a south Indian city. Nat Commun. 2023;14(1):3563.
- 2. Collaborators C-EM. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022;399(10334):1513-36
- 3. Saskia M, Marcel H, Minke H, Gertjan K. Excess mortality across countries in the Western World since the COVID-19 pandemic: â□□Our World in Dataâ□□ estimates of January 2020 to December 2022. BMJ Public Health. 2024;2(1):e000282.
- 4. Rahmani K, Shavaleh R, Forouhi M, Disfani HF, Kamandi M, Oskooi RK, et al. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. Front Public Health. 2022;10:873596.
- 5. Mimura W, Ishiguro C, Maeda M, Murata F, Fukuda H. Association between mRNA COVID-19 vaccine boosters and mortality in Japan: The VENUS study. Hum Vaccin Immunother. 2024;20(1):2350091.
- 6. Xu S, Sy LS, Hong V, Farrington P, Glenn SC, Ryan DS, et al. Mortality risk after COVID-19 vaccination: A self-controlled case series study. Vaccine. 2024;42(7):1731-7.
- 7. Stivanello E, Beghelli C, Cardoni F, Giansante C, Marzaroli P, Musti MA, et al. Short-term mortality following COVID-19 vaccination in Bologna, Italy: a one-year study. Vaccine. 2022;40(39):5709-15.
- 8. McConeghy KW, Hur K, Dahabreh IJ, Jiang R, Pandey L, Gellad WF, et al. Early Mortality After the First Dose of COVID-19 Vaccination: A Target Trial Emulation. Clin Infect Dis. 2024;78(3):625-32.
- 9. de Gier B, van Asten L, Boere TM, van Roon A, van Roekel C, Pijpers J, et al. Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021-January 2022. Vaccine. 2023;41(31):4488-96.
- 10. Lopez-Doriga Ruiz P, Gunnes N, Michael Gran J, Karlstad O, Selmer R, Dahl J, et al. Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in Norway. Vaccine. 2023;41(2):323-32.
- 11. Emergency preparedness register for COVID-19 (Beredt C19) [Available from: https://www.fhi.no/en/id/corona/coronavirus/emergency-preparedness-register-for-covid-19/.
- 12. SYSVAK Codes (only available in Norwegian) [Available from: https://www.fhi.no/va/sysvak/sysvak-koder/#sysvak-koder/.
- 13. Bakken IJ, Ariansen AMS, Knudsen GP, Johansen KI, Vollset SE. The Norwegian Patient Registry and the Norwegian Registry for Primary Health Care: Research potential of two nationwide health-care registries. Scand J Public Health. 2020;48(1):49-55.
- 14. Wu N, Joyal-Desmarais K, Ribeiro PAB, Vieira AM, Stojanovic J, Sanuade C, et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir Med. 2023;11(5):439-52.
- 15. The Health of Migrants, Refugees and those of migrant origin in Norway [Available from: https://www.fhi.no/en/he/hin/groups/health-immigrant-population/?term=.
- 16. Hansen AH, Halvorsen PA, Ringberg U, Forde OH. Socio-economic inequalities in health care utilisation in Norway: a population based cross-sectional survey. BMC Health Serv Res. 2012;12:336.
- 17. Menegale F, Manica M, Zardini A, Guzzetta G, Marziano V, d'Andrea V, et al. Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis. JAMA Netw Open. 2023;6(5):e2310650.
- 18. Statistics Norway Life expectancy fell during 2022 (only available in Norwegian) [Available from: https://www.ssb.no/befolkning/fodte-og-dode/statistikk/dode/artikler/forventa-levealder-falt-i-2022.

- 19. Mortality in Norway during the covid-19 pandemic 2020-2023 (only available in Norwegian) [Available from: https://www.fhi.no/publ/2024/dodelighet-i-norge-under-koronapandemien-2020-2023/.
- 20. Jun T, Nirenberg S, Weinberger T, Sharma N, Pujadas E, Cordon-Cardo C, et al. Analysis of sex-specific risk factors and clinical outcomes in COVID-19. Commun Med (Lond). 2021;1:3.
- 21. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-81.

Figures

Figure 1. Adjusted incidence ratios (aIRR)* of death (all causes) by vaccination status

*Adjusted for sex (man/woman), county of residence (categorical), calendar time (quarter and year) and medical risk group at baseline (yes/no)

Tables

Table 1. Study population characteristics*

Sex	Age group	Variable	Period	3+ doses	1-2 doses	No doses
Both	18-44	Total, N	2021-2023	855126	779056	412538
		Women, N (%)	2021-2023	440343 (51,5)	355564 (45,6)	204214 (49,5)
		Risk group, N (%)	2021-2023	101000 (11,8)	59342 (7,6)	20839 (5,1)
	45-64	Total, N	2021-2023	1031838	214211	206188
		Women, N (%)	2021-2023	502309 (48,7)	97423 (45,5)	108443 (52,6)
		Risk group, N (%)	2021-2023	240302 (23,3)	36508 (17,0)	35027 (17,0)
	65+	Total, N	2021-2023	1011873	72760	62320
		Women, N (%)	2021-2023	531013 (52,5)	39871 (54,8)	33540 (53,8)
		Risk group, N (%)	2021-2023	531826 (52,6)	45717 (62,8)	26105 (41,9)
Women	18-44	Total, N	2021-2023	440343	355564	204214
		Risk group, N (%)	2021-2023	57192 (13,0)	30850 (8,7)	12936 (6,3)
	45-64	Total, N	2021-2023	502309	97423	108443
		Risk group, N (%)	2021-2023	114428 (22,8)	17382 (17,8)	19497 (18,0)
	65+	Total, N	2021-2023	531013	39871	33540
		Risk group, N (%)	2021-2023	257256 (48,4)	24456 (61,3)	13705 (40,9)
Men	18-44	Total, N	2021-2023	414783	423492	208324
		Risk group, N (%)	2021-2023	43808 (10,6)	28492 (6,7)	7903 (3,8)
	45-64	Total, N	2021-2023	529529	116788	97745
		Risk group, N (%)	2021-2023	125874 (23,8)	19126 (16,4)	15530 (15,9)
	65+	Total, N	2021-2023	480860	32889	28780
		Risk group, N (%)	2021-2023	274570 (57,1)	21261 (64,6)	12400 (43,1)

^{*}Age and vaccination status is reported at the last available point of follow-up for each individual during 2021-2023. Sex and risk group status was only registered at baseline

Table 2. Unadjusted and adjusted incidence rate ratios of death (all causes) by vaccination status

							401				
				3+ doses			1-2 doses			No dose	es
Sex	Age group	Period	IRR (95% CI)	alRR (95% CI)*	Deaths (100 000 py [§])	IRR (95% CI)	aIRR (95% CI)*	Deaths (100 000 py §)	IRR (95% CI)	aIRR (95% CI)*	Deaths (100 000 py §)
Both	18-44	2021-2023	0,70 (0,64 - 0,76)	0,42 (0,38 - 0,47)	881 (17,10)	0,71 (0,66 - 0,77)	0,49 (0,45 - 0,54)	1210 (23,10)	Ref	Ref	1185 (16,10)
	45-64	2021-2023	0,73 (0,70 - 0,76)	0,39 (0,37 - 0,41)	6061 (20,54)	0,80 (0,76 - 0,83)	0,54 (0,51 - 0,57)	3616 (11,22)	Ref	Ref	3421 (8,44)
	65+	2021-2023	0,76 (0,74 - 0,77)	0,42 (0,41 - 0,43)	69545 (19,21)	0,89 (0,87 - 0,91)	0,77 (0,75 - 0,79)	30779 (7,25)	Ref	Ref	16265 (3,40)
Women	18-44	2021-2023	0,83 (0,72 - 0,96)	0,48 (0,40 - 0,58)	367 (8,80)	0,67 (0,58 - 0,77)	0,46 (0,39 - 0,54)	364 (10,85)	Ref	Ref	365 (7,24)
	45-64	2021-2023	0,78 (0,73 - 0,83)	0,41 (0,37 - 0,45)	2452 (10,02)	0,82 (0,76 - 0,88)	0,53 (0,49 - 0,59)	1372 (5,35)	Ref	Ref	1196 (3,81)
	65+	2021-2023	0,78 (0,76 - 0,8)	0,47 (0,45 - 0,48)	35836 (10,13)	0,93 (0,91 - 0,96)	0,83 (0,81 - 0,86)	16539 (3,91)	Ref	Ref	8165 (1,80)
Men	18-44	2021-2023	0,67 (0,60 - 0,75)	0,40 (0,35 - 0,45)	514 (8,30)	0,75 (0,68 - 0,82)	0,51 (0,46 - 0,57)	846 (12,24)	Ref	Ref	820 (8,86)
	45-64	2021-2023	0,71 (0,68 - 0,75)	0,38 (0,36 - 0,41)	3609 (10,52)	0,80 (0,75 - 0,84)	0,54 (0,50 - 0,58)	2244 (5,88)	Ref	Ref	2225 (4,63)
	65+	2021-2023	0,74 (0,72 - 0,75)	0,37 (0,36 - 0,39)	33709 (9,08)	0,84 (0,82 - 0,87)	0,71 (0,68 - 0,73)	14240 (3,34)	Ref	Ref	8100 (1,61)

^{*}aIRR (adjusted incidence rate ratio): Adjusted for sex (man/woman), county of residence (categorical), calendar time (quarter and year) and medical risk group at baseline (yes/no)

[§]Person years (py)

Supplemental table 1. Study population characteristics by year*

Sex	Age group	Variable	Period	3+ doses	1-2 doses	No doses
Both	18-44	Total, N	2021-2023	855126	779056	412538
			2021	144274	1465105	343136
			2022	886506	744580	277834
			2023	851555	770857	311743
		Women, N (%)	2021-2023	440343 (51,5)	355564 (45,6)	204214 (49,5)
			2021	93924 (65,1)	688623 (47,0)	166879 (48,6)
			2022	455057 (51,3)	338596 (45,5)	118410 (42,6)
			2023	438366 (51,5)	351333 (45,6)	137171 (44,0)
		Risk group, N (%)	2021-2023	101000 (11,8)	59342 (7,6)	20839 (5,1)
			2021	41598 (28,8)	122591 (8,4)	22440 (6,5)
			2022	105899 (11,9)	56641 (7,6)	12461 (4,5)
			2023	100589 (11,8)	58675 (7,6)	12156 (3,9)
	45-64	Total, N	2021-2023	1031838	214211	206188
			2021	455906	775186	181065
			2022	1036365	201982	114273
			2023	1027678	209430	125415
		Women, N (%)	2021-2023	502309 (48,7)	97423 (45,5)	108443 (52,6)
			2021	234814 (51,5)	357985 (46,2)	96257 (53,2)
			2022	504218 (48,7)	92021 (45,6)	47171 (41,3)
			2023	500589 (48,7)	95463 (45,6)	53231 (42,4)
		Risk group, N (%)	2021-2023	240302 (23,3)	36508 (17,0)	35027 (17,0)
			2021	174824 (38,3)	122491 (15,8)	36247 (20,0)
			2022	249724 (24,1)	35760 (17,7)	14555 (12,7)
			2023	237959 (23,2)	34124 (16,3)	13909 (11,1)
	65+	Total, N	2021-2023	1011873	72760	62320
			2021	853265	120800	53909
			2022	954970	47549	44385
			2023	975205	43331	45623
		Women, N (%)	2021-2023	531013 (52,5)	39871 (54,8)	33540 (53,8)
			2021	450257 (52,8)	66378 (54,9)	28808 (53,4)
			2022	502907 (52,7)	26575 (55,9)	24308 (54,8)
			2023	512086 (52,5)	24065 (55,5)	25312 (55,5)
		Risk group, N (%)	2021-2023	531826 (52,6)	45717 (62,8)	26105 (41,9)
			2021	465207 (54,5)	73254 (60,6)	26003 (48,2)
			2022	509446 (53,3)	24756 (52,1)	16647 (37,5)
			2023	500597 (51,3)	20017 (46,2)	15142 (33,2)
Women	18-44	Total, N	2021-2023	440343	355564	204214
			2021	93924	688623	166879
			2022	455057	338596	118410
			2023	438366	351333	137171
		Risk group, N (%)	2021-2023	57192 (13,0)	30850 (8,7)	12936 (6,3)

			2021	24946 (26,6)	65716 (9,5)	13898 (8,3)
			2022	59767 (13,1)	29808 (8,8)	6308 (5,3)
	45.04	T. C. I. NI	2023	56956 (13,0)	30507 (8,7)	6122 (4,5)
	45-64	Total, N	2021-2023	502309	97423	108443
			2021	234814	357985	96257
			2022	504218	92021	47171
			2023	500589	95463	53231
		Risk group, N (%)	2021-2023	114428 (22,8)	17382 (17,8)	19497 (18,0)
			2021	82461 (35,1)	56987 (15,9)	20034 (20,8)
			2022	118002 (23,4)	16943 (18,4)	6716 (14,2)
			2023	113439 (22,7)	16363 (17,1)	6482 (12,2)
	65+	Total, N	2021-2023	531013	39871	33540
			2021	450257	66378	28808
			2022	502907	26575	24308
			2023	512086	24065	25312
		Risk group, N (%)	2021-2023	257256 (48,4)	24456 (61,3)	13705 (40,9)
			2021	225251 (50,0)	38924 (58,6)	13812 (47,9)
			2022	246849 (49,1)	13391 (50,4)	9059 (37,3)
			2023	241369 (47,1)	10804 (44,9)	8224 (32,5)
Men	18-44	Total, N	2021-2023	414783	423492	208324
			2021	50350	776482	176257
			2022	431449	405984	159424
			2023	413189	419524	174572
		Risk group, N (%)	2021-2023	43808 (10,6)	28492 (6,7)	7903 (3,8)
		3 - 17, (-1,	2021	16652 (33,1)	56875 (7,3)	8542 (4,8)
			2022	46132 (10,7)	26833 (6,6)	6153 (3,9)
			2023	43633 (10,6)	28168 (6,7)	6034 (3,5)
	45-64	Total, N	2021-2023	529529	116788	97745
		,	2021	221092	417201	84808
			2022	532147	109961	67102
			2023	527089	113967	72184
		Risk group, N (%)	2021-2023	125874 (23,8)	19126 (16,4)	15530 (15,9)
		rtisk group, rt (70)	2021 2023	92363 (41,8)	65504 (15,7)	16213 (19,1)
			2021	131722 (24,8)	18817 (17,1)	7839 (11,7)
			2022	124520 (23,6)		
	CE .	Total N		, , ,	17761 (15,6)	7427 (10,3)
	65+	Total, N	2021-2023	480860	32889	28780
			2021	403008	54422	25101
			2022	452063	20974	20077
			2023	463119	19266	20311
		Risk group, N (%)	2021-2023	274570 (57,1)	21261 (64,6)	12400 (43,1)
			2021	239956 (59,5)	34330 (63,1)	12191 (48,6)
			2022	262597 (58,1)	11365 (54,2)	7588 (37,8)
			2023	259228 (56,0)	9213 (47,8)	6918 (34,1)

*Age and vaccination status is reported at the last available point of follow-up for each individual during the given period. Sex and risk group status was only registered at baseline

Supplemental table 2. Unadjusted and adjusted incidence rate ratios of death (all causes) by vaccination status and year

			3+ doses		1-2 doses			No doses			
Sex	Age group	Period	IRR (95% CI)	aIRR (95% CI)*	Deaths (100 000 py §)	IRR (95% CI)	aIRR (95% CI)*	Deaths (100 000 py [§])	IRR (95% CI)	aIRR (95% CI)*	Deaths (100 000 py §)
Both	18-44	2021-2023	0,70 (0,64 - 0,76)	0,42 (0,38 - 0,47)	881 (17,10)	0,71 (0,66 - 0,77)	0,49 (0,45 - 0,54)	1210 (23,10)	Ref	Ref	1185 (16,10)
		2021	2,52 (1,45 - 4,36)	0,84 (0,47 - 1,49)	13 (0,09)	0,79 (0,69 - 0,90)	0,46 (0,39 - 0,55)	356 (7,72)	Ref	Ref	631 (10,79)
		2022	0,46 (0,39 - 0,54)	0,40 (0,34 - 0,47)	393 (8,36)	0,55 (0,47 - 0,64)	0,53 (0,45 - 0,62)	440 (7,85)	Ref	Ref	255 (2,50)
		2023	0,52 (0,45 - 0,60)	0,46 (0,39 - 0,53)	475 (8,65)	0,52 (0,45 - 0,60)	0,48 (0,41 - 0,56)	414 (7,52)	Ref	Ref	299 (2,81)
	45-64	2021-2023	0,73 (0,70 - 0,76)	0,39 (0,37 - 0,41)	6061 (20,54)	0,80 (0,76 - 0,83)	0,54 (0,51 - 0,57)	3616 (11,22)	Ref	Ref	3421 (8,44)
		2021	1,53 (1,27 - 1,83)	0,49 (0,40 - 0,60)	124 (0,24)	0,86 (0,81 - 0,92)	0,48 (0,44 - 0,53)	2048 (6,90)	Ref	Ref	2144 (6,25)
		2022	0,46 (0,42 - 0,50)	0,36 (0,33 - 0,39)	2895 (10,04)	0,66 (0,59 - 0,73)	0,60 (0,54 - 0,66)	937 (2,28)	Ref	Ref	656 (1,05)
		2023	0,55 (0,50 - 0,60)	0,45 (0,41 - 0,49)	3042 (10,27)	0,57 (0,51 - 0,64)	0,53 (0,47 - 0,59)	631 (2,04)	Ref	Ref	621 (1,15)
	65+	2021-2023	0,76 (0,74 - 0,77)	0,42 (0,41 - 0,43)	69545 (19,21)	0,89 (0,87 - 0,91)	0,77 (0,75 - 0,79)	30779 (7,25)	Ref	Ref	16265 (3,40)
		2021	0,98 (0,95 - 1,02)	0,62 (0,59 - 0,65)	3377 (0,90)	1,00 (0,97 - 1,02)	0,82 (0,80 - 0,85)	23942 (6,27)	Ref	Ref	9945 (2,60)
		2022	0,39 (0,38 - 0,41)	0,34 (0,33 - 0,35)	32445 (9,00)	0,91 (0,87 - 0,95)	0,79 (0,76 - 0,83)	4669 (0,56)	Ref	Ref	3637 (0,40)
		2023	0,55 (0,53 - 0,57)	0,47 (0,45 - 0,49)	33723 (9,31)	0,78 (0,74 - 0,83)	0,70 (0,66 - 0,74)	2168 (0,42)	Ref	Ref	2683 (0,41)
Women	18-44	2021-2023	0,83 (0,72 - 0,96)	0,48 (0,40 - 0,58)	367 (8,80)	0,67 (0,58 - 0,77)	0,46 (0,39 - 0,54)	364 (10,85)	Ref	Ref	365 (7,24)
		2021	3,99 (2,11 - 7,52)	1,20 (0,59 - 2,41)	10 (0,06)	0,76 (0,61 - 0,94)	0,46 (0,34 - 0,62)	123 (3,84)	Ref	Ref	211 (4,98)
		2022	0,56 (0,43 - 0,74)	0,45 (0,34 - 0,60)	170 (4,30)	0,48 (0,36 - 0,64)	0,45 (0,33 - 0,60)	120 (3,59)	Ref	Ref	73 (1,04)
		2023	0,63 (0,49 - 0,82)	0,50 (0,39 - 0,66)	187 (4,44)	0,53 (0,40 - 0,70)	0,48 (0,36 - 0,64)	121 (3,43)	Ref	Ref	81 (1,22)
	45-64	2021-2023	0,78 (0,73 - 0,83)	0,41 (0,37 - 0,45)	2452 (10,02)	0,82 (0,76 - 0,88)	0,53 (0,49 - 0,59)	1372 (5,35)	Ref	Ref	1196 (3,81)
		2021	1,65 (1,26 - 2,17)	0,55 (0,40 - 0,75)	56 (0,13)	0,94 (0,85 - 1,04)	0,55 (0,47 - 0,63)	826 (3,37)	Ref	Ref	752 (2,89)
		2022	0,46 (0,39 - 0,53)	0,36 (0,32 - 0,42)	1141 (4,89)	0,63 (0,53 - 0,74)	0,58 (0,49 - 0,69)	335 (1,04)	Ref	Ref	220 (0,43)
		2023	0,54 (0,47 - 0,63)	0,44 (0,38 - 0,51)	1255 (5,00)	0,49 (0,41 - 0,59)	0,45 (0,37 - 0,54)	211 (0,93)	Ref	Ref	224 (0,49)
	65+	2021-2023	0,78 (0,76 - 0,8)	0,47 (0,45 - 0,48)	35836 (10,13)	0,93 (0,91 - 0,96)	0,83 (0,81 - 0,86)	16539 (3,91)	Ref	Ref	8165 (1,80)
		2021	1,08 (1,02 - 1,14)	0,72 (0,67 - 0,77)	1876 (0,48)	1,05 (1,02 - 1,09)	0,92 (0,87 - 0,96)	12853 (3,36)	Ref	Ref	4900 (1,35)
		2022	0,41 (0,40 - 0,43)	0,38 (0,36 - 0,40)	16638 (4,75)	0,96 (0,91 - 1,02)	0,85 (0,80 - 0,90)	2531 (0,31)	Ref	Ref	1844 (0,22)
		2023	0,57 (0,54 - 0,6)	0,50 (0,48 - 0,53)	17322 (4,90)	0,78 (0,72 - 0,85)	0,70 (0,65 - 0,76)	1155 (0,24)	Ref	Ref	1421 (0,23)
Men	18-44	2021-2023	0,67 (0,60 - 0,75)	0,40 (0,35 - 0,45)	514 (8,30)	0,75 (0,68 - 0,82)	0,51 (0,46 - 0,57)	846 (12,24)	Ref	Ref	820 (8,86)
		2021	1,42 (0,46 - 4,43)	0,42 (0,13 - 1,33)	3 (0,03)	0,83 (0,71 - 0,98)	0,47 (0,38 - 0,58)	233 (3,88)	Ref	Ref	420 (5,81)
		2022	0,44 (0,36 - 0,53)	0,37 (0,30 - 0,45)	223 (4,06)	0,60 (0,50 - 0,72)	0,57 (0,47 - 0,68)	320 (4,26)	Ref	Ref	182 (1,46)
		2023	0,50 (0,42 - 0,60)	0,43 (0,36 - 0,52)	288 (4,20)	0,52 (0,44 - 0,62)	0,49 (0,41 - 0,58)	293 (4,10)	Ref	Ref	218 (1,59)
	45-64	2021-2023	0,71 (0,68 - 0,75)	0,38 (0,36 - 0,41)	3609 (10,52)	0,80 (0,75 - 0,84)	0,54 (0,50 - 0,58)	2244 (5,88)	Ref	Ref	2225 (4,63)
		2021	1,54 (1,21 - 1,96)	0,46 (0,35 - 0,60)	68 (0,11)	0,83 (0,77 - 0,90)	0,45 (0,40 - 0,51)	1222 (3,53)	Ref	Ref	1392 (3,35)
		2022	0,48 (0,44 - 0,54)		1754 (5,15)		0,61 (0,54 - 0,70)	602 (1,24)	Ref	Ref	436 (0,62)
		2023	0,57 (0,51 - 0,63)	0,46 (0,41 - 0,51)	1787 (5,27)	0,63 (0,55 - 0,72)	0,58 (0,51 - 0,67)	420 (1,11)	Ref	Ref	397 (0,66)
	65+	2021-2023	0,74 (0,72 - 0,75)	0,37 (0,36 - 0,39)	33709 (9,08)	0,84 (0,82 - 0,87)	0,71 (0,68 - 0,73)	14240 (3,34)	Ref	Ref	8100 (1,61)

	2021	0,89 (0,84 - 0,94)	0,51 (0,47 - 0,55)	1501 (0,42)	0,94 (0,91 - 0,97)	0,73 (0,69 - 0,76)	11089 (2,91)	Ref	Ref	5045 (1,24)	
	2022	0,37 (0,35 - 0,39)	0,31 (0,29 - 0,32)	15807 (4,25)	0,86 (0,81 - 0,92)	0,73 (0,69 - 0,78)	2138 (0,25)	Ref	Ref	1793 (0,18)	
	2023	0,54 (0,51 - 0,57)	0,44 (0,42 - 0,47)	16401 (4,41)	0,78 (0,72 - 0,85)	0,69 (0,63 - 0,75)	1013 (0,19)	Ref	Ref	1262 (0,18)	

^{*}alRR (adjusted incidence rate ratio): Adjusted for sex (man/woman), county of residence (categorical), calendar time (quarter and year) and medical risk group at baseline (yes/no)

[§]Person years (py)

medRxiv preprint doi: https://doi.org/10.1101/2024.12.15.24319058; this version posted December 16, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Supplemental table 3. Definition of preexisting risk conditions with increased risk of severe covid-19 disease

					Number of
Diala massa	100.40	ICPC-2	Norwegian Clinical Prosedure	F	registrations
Risk group	ICD-10	ICPC-2	Codes KAS10, KAS11, KAS20, KAS21,	From	required
			JLE00, JLE03, JLE10, JLE16,		
Organ transplant	Z94.0, Z94.1, Z94.2, Z94.3, Z94.4, Z94.8		JJC00, JJC10, JJC20	prior to or at baseline	2
Neurological or muscular disease	G1, G20, G21, G23, G24, G40.5, G61.0, G70, G71,		33333, 3331.3, 33323	p.1.0. 10 0. at 20000	_
with impaired coughing strength or	G80.0, G80.2, G80.3, F72, F73, F84.0, F84.1, Q05.0,				₫.
lung function	Q05.1, Q05.2, Q05.3, Q05.4, Q05.5, Q05.6, Q90			prior to or at baseline	2 5
					nad
Chronic kidney disease or					(D)
significantly impaired renal function	N18.3, N18.4, N18.5		JAGD30, JAGD31	prior to or at baseline	2 🐇
Chronic liver disease or					lab
significantly impaired liver function	K70.4, K72			prior to or at baseline	2 c
oigninioantily impaired in or raneaem	W 0.4, W 2			prior to or at bassimo	t is made available under a C
					er
Diabetes	E10, E11, E12, E13, E14	T89, T90		prior to or at baseline	
					ŷ
O					- 8
Chronic lung disease	J41, J42, J43, J44, J45, J46, J47, J84, J98, E84	R95, R96		prior to or at baseline	2 ½
					ž
Obesity	E66	T82		prior to or at baseline	2 2 2 2 2 2
Coccity	200	102		prior to or at bacomin	
	C81, C82, C83, C84, C85, C86, C87, C88, C89, C90,				nte
Hematologic (blood) cancer	C91, C92, C93, C94, C95, C96, D45, D45, D47		AAG	prior to or at baseline	2 Internal
					at io
Land to Cartain	D00 D04 D00 D00 D04				ational license
Immunodeficiency	D80, D81, D82, D83, D84			prior to or at baseline	2
	105, 106, 107, 108, 109, 12, 131, 132, 134, 135, 136, 137,	K74, K75, K76, K77,			ens
Cardiovascular disease	139, 140, 141, 142, 143, 146, 148, 149, 150	K78, K82, K83, K87		prior to or at baseline	2 .
	100, 110, 111, 112, 110, 110, 110, 110	117 0, 1102, 1100, 1107		prior to or at bacomin	
	160, 161, 162, 163, 164, 169.1, 169.2, 169.3, 169.4, 169.8,				
Stroke	169.0	K90, K91		prior to or at baseline	2
Dementia and related mental	F0 000 004	B=0			
illnesses	F0, G30, G31	P70		prior to or at baseline	2
Other active cancer, ongoing or			MEGA MEGA MEGA MEGA		
recently finished treatment for cancer	C0, C1, C2, C3, C4, C5, C6, C7, C80		WEOA, WEOB, WEOC, WBOC, WBGM, RAGG	at baseline	6
Caricer	00, 01, 02, 03, 04, 03, 00, 07, 000		WDGW, RAGG	at paseillie	U

Diseases that can require G35, M05, M08, M06, M07, M09, M13, M14, K50, immunosuppressive therapy K51 prior to or at baseline 2

All codes are described in further detail at: https://beta.finnkode.ehelse.no (in Norwegian)

The stated codes include all subcodes, meaning that, for example, E10 includes all codes starting with E10, such as E10.0, E10.2, E10.9 etc, while F0 includes F00.0-F09.9

